Hear what this leading medical oncologist has to say about liquid biopsy
Home » Hear what this leading medical oncologist has to say about liquid biopsy

GH AMEA on Social MediaHear what this leading medical oncologist has to say about liquid biopsy
Hear what this leading medical oncologist has to say about liquid biopsy
Hear what this leading medical oncologist has to say about liquid biopsy
LinkedIn

Hear what this leading medical oncologist has to say about liquid biopsy… Dr Vassiliki Papadimitrakopoulou sharing highlights of the “NILE study which was a prospective clinical trial comparing standard-of-care tissue testing for patients with metastatic non-small cell lung cancer for molecular profiling with NGS that was performed at the same time at study entry on blood specimens obtained from the same patients. This is the first prospective clinical trial to compare NGS performed via a standardized highly sensitive assay in the blood plasma with standard-of-care tissue testing”. Click on the video to learn more about the NILE study, where the Guardant360® assay was utilized. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Guardant360®. Test. Take Action.

Open chat
Message us